CLINICAL_TRIALS
trial_result
· 2022-02-02
Clinical Trial Update: Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype [Phase 2]
Summary
Phase 2 trial evaluating VX-814 for Alpha 1-Antitrypsin Deficiency (PiZZ genotype) was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: TERMINATED | Results posted: 2022-02-02